This volume reviews the new potential treatments and research in the
area of Alzheimer's disease. Special attention is given to international
developments in all fields relevant to new drug development. Topics
discussed include: progress in the international harmonization of drug
development guidelines for dementia drugs; bioethics and law;
development of rating instruments; behavioural treatments; and the
activities of the Reagan Foundation. The text integrates basic and
clinical research findings, and provides evaluation of new approaches to
therapy by world leaders in the field. The potential benefit for
Alzheimer patients and families resulting from these research
programmes, from molecular biology to clinical pharmacology, is reviewed
and evaluated.